



3rd Italy - USA Meeting

Hereditary Breast & Ovarian Cancers:

Networking to address biological and therapeutic challenges

March 25 2015

Sala della Provincia - Bari

March 26 - 27

Istituto Tumori "Giovanni Paolo II" - Bari

Chairs: A. Paradiso, S. Tommasi, F. Esteva, F. Muggia



Ministero della Salute



Regione Puglia



Comune di Bari
con il Patrocinio del Comune di Bari
Assessorato al Welfare
ai sensi del vigente Regolamento

13.00 Welcome

Site: Sala della Provincia - Bari

Wednesday 25

16.00 Opening Session

F. Muggia (New York), A. Paradiso (Bari)

16.30 Welcome of authorities

17.00 *The Sass Foundation Lecture: lessons learned from HBOC*
M. Pike (New York)

Session I: International networks: HBOC consortia and database

T. Safra (Tel Aviv), P. Peterlongo (Milano)

18.00 German Consortium for Hereditary Breast and Ovarian Cancer

K. Rhiem (Koln)

18.20 The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

P. Peterlongo (Milano)

18.40 Evidence-based Network for the Interpretation of Germline
Mutant Alleles (ENIGMA)

D. Goldgar (New York)

Reserved only for invited guests:

19.00 Welcome *cheese and wine*

20.30 Guided tour at the Art Gallery - Pinacoteca Provinciale of Bari

Session II: Genetic risk and modifiers

M.A. Pujana (Barcelona), S. Tommasi (Bari)

Thursday 26

8.00 Posters set up and viewing

8.30 Haploinsufficiency of BRCA1 & 2: the role in breast cancer pathogenesis
S. Pathania (Boston)

9.00 Clinical applications of coding and non-coding RNA expression
profiling in breast cancer

F. Esteva (New York)

9.30 Hereditary breast cancer: even more pieces to the polygenic puzzle

T. Doerk (Hannover)



MYRIAD.



A Thermo Fisher Scientific Brand



BRUNO FORNITURE
CONSULTING

Program

Hereditary Breast & Ovarian Cancers:

Networking to address biological and therapeutic challenges

10.00 Other breast cancer predisposition genes: are we ready for gene panel testing ?

M.A. Caligo (*Pisa*)

Thursday 26

10.30 miRNA pattern in HBOC

S. Tommasi (*Bari*)

11.00 **Coffee Break; posters viewing**

11.15 Functional assays for analysis of variants of uncertain significance in BRCA2

A. Carreira (*Orsay*)

11.45 The effect of BRCA1 wildtype allele as a modifier of breast cancer risk in BRCA1 mutation carriers

M.A. Pujana (*Barcelona*)

12.00 Distinct immune characteristics in women with germline BRCA1/2 mutations (gBRCAm)-related high-grade serous

J-M Lee (*Bethesda*)

12.15 Myriad: Myrisk panel - L. Varesco (*Genova*)

13.00 **Lunch; posters viewing**

Session III: Risk communication - social and medical aspects

(in cooperation with Association of European Cancer League)

B. Bonanni (*Milano*), V. Smaildone (*New York*)

14.30 The perception of cancer risk

R. Foster (*Dublin*)

15.00 Tailored communication of hereditary cancer risk

E. Razzaboni (*Modena*)

15.30 New models for genetic counseling

L. Varesco (*Genova*)

16.00 **Coffee Break; posters viewing**

16.15 Diet and BRCA risk

P. Pasanisi (*Milano*)

16.45 Clinical management of Uncertain Significance Variant (VUS) in HBOC: a survey of genetic counselling practice

F. Carbonardi (*Mantova*)

17.00 Study of old women carrying BRCA1/2 mutations but that have not developed cancer: a model of cancer resilience

J. Brunet (*Barcelona*)

17.15 Genetic counseling. What about nurse's role?

I. Feroce (*Milano*)

17.30 Heritability of breast cancer susceptibility in Apulian families

S. De Summa (*Bari*)

17.45 Integration of genetic testing and counseling into oncologic care of underserved breast and ovarian cancer patients:

The Los Angeles County + University of Southern California Experience
C. Ricker (*Los Angeles*)

Hereditary Breast & Ovarian Cancers:

Networking to address biological and therapeutic challenges

Session IV: Implications for prevention & treatment

Friday 27

S. Formenti (New York), A. Paradiso (Bari)

- 9.00 Panel discussion on issues in chemoprevention, early diagnosis, surgery, radiation, and systemic therapies including PARP inhibitors - Case presentation and discussion

E. Warner (Toronto) - Population screening

C. Thomssen (Halle) - Surgical prevention

B. Bonanni (Milano) - Pharmacological prevention

F. Arena (New York) - Special issue with triple negative

H. Calvert (London) - Future direction in prevention and treatment

11.00 Coffee Break

- 11.15 **Lynne Cohen Foundation Lecture:**
BRCA status and its effect on treatment results in ovarian cancer
T. Safra (Tel Aviv)

- 11.45 Triple Negative Breast Cancer: results of a Phase I-II study of adjuvant concurrent carboplatin and radiation
S. Formenti (New York)

- 12.00 Next-Generation Sequencing in Male Breast cancer: results from a 94-gene sequencing panel
V. Zampiga (Meldola)

- 12.15 Clinical activity of low dose oral cyclophosphamide (C) plus the poly-ADP-ribose- polymerase(PARP) inhibitor veliparib (V) in BRCA mutation associated metastatic breast cancer (MBC): preliminary results from an ongoing clinical trial P8853
J. Anampa (New York)

13.15 Lunch

Session V: New insights

F. Arena (New York)

- 14.30 Developments of the IBIS (Tyrer-Cuzick) Breast Cancer Risk Model
A. Brentnall (London)

- 15.00 The case for lobular breast cancer in HDGC syndrome
B. Bonanni (Milano)

- 15.30 Integrating genetic and epigenetic data for the discovery of genetic interactions associated with cancer risk.
M.A. Pujana (Barcellona)

- 16.00 General Discussion

- 16.30 Awards Presentation

- 17.00 Future perspectives and conclusions
A. Paradiso (Bari), F. Muggia (New York)